Precipio Inc (PRPO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Precipio Inc (PRPO) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($10.00K) by net assets ($13.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PRPO market cap for the company's overall valuation and market capitalisation.
Precipio Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Precipio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Precipio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Precipio Inc ranked by their cash flow conversion efficiency. Explore Precipio Inc (PRPO) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sentronic International
TWO:3232
|
-0.106x |
|
Almondz Global Securities Limited
NSE:ALMONDZ
|
-0.002x |
|
Metrod Holdings Bhd
KLSE:6149
|
0.290x |
|
Ilshinstone
KO:007110
|
-0.001x |
|
Rand Capital Corp
NASDAQ:RAND
|
0.009x |
|
Digitalx Ltd
AU:DCC
|
-0.023x |
|
Profoto Holding AB
ST:PRFO
|
0.022x |
|
Pantaflix AG
XETRA:PAL
|
1.592x |
Annual Cash Flow Conversion Efficiency for Precipio Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Precipio Inc from 1999 to 2024. View PRPO live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $12.09 Million | $439.00K | 0.036x | +114.72% |
| 2023-12-31 | $14.43 Million | $-3.56 Million | -0.247x | +47.71% |
| 2022-12-31 | $16.37 Million | $-7.72 Million | -0.472x | -76.47% |
| 2021-12-31 | $24.60 Million | $-6.58 Million | -0.267x | +49.08% |
| 2020-12-31 | $14.16 Million | $-7.43 Million | -0.525x | +24.17% |
| 2019-12-31 | $13.21 Million | $-9.14 Million | -0.692x | +37.24% |
| 2018-12-31 | $6.12 Million | $-6.75 Million | -1.103x | -114.76% |
| 2017-12-31 | $13.03 Million | $-6.69 Million | -0.514x | -379.96% |
| 2016-12-31 | $-19.35 Million | $-3.55 Million | 0.183x | -81.00% |
| 2015-12-31 | $-12.82 Million | $-12.38 Million | 0.966x | +146.18% |
| 2014-12-31 | $6.55 Million | $-13.70 Million | -2.091x | -182.46% |
| 2013-12-31 | $11.45 Million | $-8.47 Million | -0.740x | -47.08% |
| 2012-12-31 | $20.27 Million | $-10.20 Million | -0.503x | -2627.50% |
| 2011-12-31 | $11.05 Million | $220.00K | 0.020x | +109.85% |
| 2010-12-31 | $8.50 Million | $-1.72 Million | -0.202x | -286.04% |
| 2009-12-31 | $11.66 Million | $1.27 Million | 0.109x | +447.37% |
| 2008-12-31 | $13.21 Million | $-413.00K | -0.031x | +84.99% |
| 2007-12-31 | $14.10 Million | $-2.94 Million | -0.208x | -175.78% |
| 2006-12-31 | $16.04 Million | $-1.21 Million | -0.076x | +62.69% |
| 2005-12-31 | $17.91 Million | $-3.63 Million | -0.203x | +63.20% |
| 2004-12-31 | $16.54 Million | $-9.10 Million | -0.550x | -87.24% |
| 2003-12-31 | $45.06 Million | $-13.24 Million | -0.294x | -0.77% |
| 2002-12-31 | $61.51 Million | $-17.94 Million | -0.292x | -115.44% |
| 2001-12-31 | $82.10 Million | $-11.12 Million | -0.135x | -110.93% |
| 2000-12-31 | $73.97 Million | $-4.75 Million | -0.064x | -101.54% |
| 1999-12-31 | $-2.10 Million | $-8.74 Million | 4.165x | -- |
About Precipio Inc
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomar… Read more